Showing results (121-130 of 152) with videos related to

Sort By:
Pageof 16
International Journal of Cancer|September 9, 2022
Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapyDeniz Can Guven, Fatma Gul Gulbahce Incesu, Hasan Cagri Yildirim, et al.
BMJ Supportive & Palliative Care|July 16, 2020
COVID-19 pandemic: changes in cancer admissionsDeniz Can Guven, Burak Yasin Aktas, Melek Seren Aksun, et al.
Anti-Cancer Drugs|February 2, 2023
The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitorsDeniz Can Guven, Deniz Aral Ozbek, Taha Koray Sahin, et al.
Integrative Cancer Therapies|October 5, 2024
The Use of Herbal Medicine and Dietary Supplements in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Cross-Sectional StudyFatih Kus, Deniz Can Guven, Hasan Cagri Yildirim, et al.
Cancer Biomarkers : Section a of Disease Markers|December 27, 2021
The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitorsDeniz Can Guven, Oktay Halit Aktepe, Melek Seren Aksun, et al.
Cancer Medicine|December 23, 2023
The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) studyDeniz Can Guven, Musa Baris Aykan, Harun Muglu, et al.
BMJ Supportive & Palliative Care|October 29, 2021
Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortalityDeniz Can Guven, Taha Koray Sahin, Hasan Cagri Yildirim, et al.
Journal of Clinical Medicine|February 27, 2026
Efficacy, Safety, and Survival Outcomes of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient Colorectal Cancer: A Retrospective, Multicenter StudyMehmet Cihan İcli, Deniz Can Guven, Arif Akyildiz, et al.
Future Oncology (London, England)|February 8, 2024
Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancerCengiz Karacin, Veli Sunar, Zuhat Urakci, et al.
Medicine|July 26, 2024
The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancerHasan Cagri Yildirim, Mustafa Buyukkor, Gözde Kavgaci, et al.
Pageof 16